ASX - By Stock
|
PAA |
Re:
STRIKE Trial - Phase 2 / 3 - The final frontier to commercial outcome
|
|
pi065509
|
17 |
2.5K |
4 |
08/06/24 |
08/06/24 |
ASX - By Stock
|
17
|
2.5K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
pi065509
|
148 |
31K |
7 |
07/06/24 |
07/06/24 |
ASX - By Stock
|
148
|
31K
|
7
|
|
ASX - By Stock
|
PAA |
Re:
Pipeline-in-a-drug
|
|
pi065509
|
61 |
10K |
13 |
06/06/24 |
06/06/24 |
ASX - By Stock
|
61
|
10K
|
13
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
pi065509
|
510 |
117K |
6 |
06/06/24 |
06/06/24 |
ASX - By Stock
|
510
|
117K
|
6
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
pi065509
|
510 |
117K |
10 |
06/06/24 |
06/06/24 |
ASX - By Stock
|
510
|
117K
|
10
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Executive team strengthened, appointment of MD/CEO & new CSO
|
|
pi065509
|
85 |
20K |
13 |
31/05/24 |
31/05/24 |
ASX - By Stock
|
85
|
20K
|
13
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
pi065509
|
510 |
117K |
9 |
20/05/24 |
20/05/24 |
ASX - By Stock
|
510
|
117K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
PAA TOP HOLDERS MOVEMENTS AS AT 30 APRIL 2024
|
|
pi065509
|
19 |
5.9K |
9 |
19/05/24 |
19/05/24 |
ASX - By Stock
|
19
|
5.9K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust appoints Sergio Duchini as Non-Executive Chairman
|
|
pi065509
|
58 |
15K |
5 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
58
|
15K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Investor update
|
|
pi065509
|
86 |
20K |
5 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
86
|
20K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Investor update
|
|
pi065509
|
86 |
20K |
5 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
86
|
20K
|
5
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Great Pharmaust FDA ODD Approval Sweepstake
|
|
pi065509
|
222 |
47K |
4 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
222
|
47K
|
4
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
pi065509
|
1.4K |
359K |
6 |
16/05/24 |
16/05/24 |
ASX - By Stock
|
1.4K
|
359K
|
6
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
pi065509
|
1.4K |
359K |
7 |
16/05/24 |
16/05/24 |
ASX - By Stock
|
1.4K
|
359K
|
7
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
pi065509
|
1.4K |
359K |
5 |
16/05/24 |
16/05/24 |
ASX - By Stock
|
1.4K
|
359K
|
5
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
pi065509
|
1.4K |
359K |
8 |
16/05/24 |
16/05/24 |
ASX - By Stock
|
1.4K
|
359K
|
8
|
|
ASX - By Stock
|
PAA |
Re:
Pharmaust to test MPL effectiveness on Alzheimer's and Parkinson's
|
|
pi065509
|
42 |
9.4K |
5 |
15/05/24 |
15/05/24 |
ASX - By Stock
|
42
|
9.4K
|
5
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
pi065509
|
1.4K |
359K |
15 |
15/05/24 |
15/05/24 |
ASX - By Stock
|
1.4K
|
359K
|
15
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Investor update
|
|
pi065509
|
86 |
20K |
14 |
14/05/24 |
14/05/24 |
ASX - By Stock
|
86
|
20K
|
14
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Board Changes
|
|
pi065509
|
250 |
62K |
10 |
12/05/24 |
12/05/24 |
ASX - By Stock
|
250
|
62K
|
10
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Board Changes
|
|
pi065509
|
250 |
62K |
6 |
11/05/24 |
11/05/24 |
ASX - By Stock
|
250
|
62K
|
6
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Board Changes
|
|
pi065509
|
250 |
62K |
13 |
11/05/24 |
11/05/24 |
ASX - By Stock
|
250
|
62K
|
13
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
pi065509
|
83 |
24K |
7 |
08/05/24 |
08/05/24 |
ASX - By Stock
|
83
|
24K
|
7
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
pi065509
|
83 |
24K |
7 |
08/05/24 |
08/05/24 |
ASX - By Stock
|
83
|
24K
|
7
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Great Pharmaust FDA ODD Approval Sweepstake
|
|
pi065509
|
222 |
47K |
3 |
07/05/24 |
07/05/24 |
ASX - By Stock
|
222
|
47K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
Corporate action
|
|
pi065509
|
239 |
64K |
33 |
07/05/24 |
07/05/24 |
ASX - By Stock
|
239
|
64K
|
33
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
pi065509
|
1.4K |
359K |
11 |
01/05/24 |
01/05/24 |
ASX - By Stock
|
1.4K
|
359K
|
11
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
pi065509
|
1.4K |
359K |
1 |
01/05/24 |
01/05/24 |
ASX - By Stock
|
1.4K
|
359K
|
1
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
pi065509
|
1.4K |
359K |
6 |
30/04/24 |
30/04/24 |
ASX - By Stock
|
1.4K
|
359K
|
6
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
pi065509
|
1.4K |
359K |
7 |
30/04/24 |
30/04/24 |
ASX - By Stock
|
1.4K
|
359K
|
7
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Appendix 4C & Quarterly Update
|
|
pi065509
|
104 |
20K |
5 |
30/04/24 |
30/04/24 |
ASX - By Stock
|
104
|
20K
|
5
|
|
ASX - By Stock
|
PAA Biotech |
Re:
Walk to Defeat MND
|
|
pi065509
|
32 |
9.8K |
3 |
28/04/24 |
28/04/24 |
ASX - By Stock
|
32
|
9.8K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Resignation of Dr Michael Thurn & appointment of John Clark
|
|
pi065509
|
261 |
71K |
4 |
24/04/24 |
24/04/24 |
ASX - By Stock
|
261
|
71K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Resignation of Dr Michael Thurn & appointment of John Clark
|
|
pi065509
|
261 |
71K |
6 |
23/04/24 |
23/04/24 |
ASX - By Stock
|
261
|
71K
|
6
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
pi065509
|
1.4K |
359K |
9 |
15/04/24 |
15/04/24 |
ASX - By Stock
|
1.4K
|
359K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Final Ethics Approval for Open-Label MND Extension Study
|
|
pi065509
|
77 |
19K |
12 |
10/04/24 |
10/04/24 |
ASX - By Stock
|
77
|
19K
|
12
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
pi065509
|
1.4K |
359K |
12 |
08/04/24 |
08/04/24 |
ASX - By Stock
|
1.4K
|
359K
|
12
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Great Pharmaust FDA ODD Approval Sweepstake
|
|
pi065509
|
222 |
47K |
4 |
02/04/24 |
02/04/24 |
ASX - By Stock
|
222
|
47K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Mainstream media is GO
|
|
pi065509
|
31 |
11K |
13 |
02/04/24 |
02/04/24 |
ASX - By Stock
|
31
|
11K
|
13
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Application for quotation of securities - PAA
|
|
pi065509
|
33 |
8.8K |
9 |
28/03/24 |
28/03/24 |
ASX - By Stock
|
33
|
8.8K
|
9
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
pi065509
|
1.4K |
359K |
4 |
27/03/24 |
27/03/24 |
ASX - By Stock
|
1.4K
|
359K
|
4
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Great Pharmaust FDA ODD Approval Sweepstake
|
|
pi065509
|
222 |
47K |
3 |
20/03/24 |
20/03/24 |
ASX - By Stock
|
222
|
47K
|
3
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Great Pharmaust FDA ODD Approval Sweepstake
|
|
pi065509
|
222 |
47K |
4 |
18/03/24 |
18/03/24 |
ASX - By Stock
|
222
|
47K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Positive clinical data filed with FDA to support ODD request
|
|
pi065509
|
100 |
27K |
15 |
14/03/24 |
14/03/24 |
ASX - By Stock
|
100
|
27K
|
15
|
|
ASX - By Stock
|
PAA |
Re:
Big Pharma buyouts.
|
|
pi065509
|
39 |
9.5K |
8 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
39
|
9.5K
|
8
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
pi065509
|
1.4K |
359K |
3 |
12/03/24 |
12/03/24 |
ASX - By Stock
|
1.4K
|
359K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
Amylyx class action Relyvrio
|
|
pi065509
|
58 |
15K |
22 |
08/03/24 |
08/03/24 |
ASX - By Stock
|
58
|
15K
|
22
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Application for quotation of securities - PAA
|
|
pi065509
|
77 |
20K |
11 |
07/03/24 |
07/03/24 |
ASX - By Stock
|
77
|
20K
|
11
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Application for quotation of securities - PAA
|
|
pi065509
|
77 |
20K |
4 |
07/03/24 |
07/03/24 |
ASX - By Stock
|
77
|
20K
|
4
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
pi065509
|
1.4K |
359K |
12 |
07/03/24 |
07/03/24 |
ASX - By Stock
|
1.4K
|
359K
|
12
|
|